» Articles » PMID: 24115702

Diabetes and Renal Disease: Who Does What?

Overview
Journal Clin Med (Lond)
Specialty General Medicine
Date 2013 Oct 12
PMID 24115702
Citations 4
Authors
Affiliations
Soon will be listed here.
Abstract

Care of patients with diabetes and chronic kidney disease (CKD) in the UK is divided between primary care, diabetologists and nephrology. In a retrospective analysis, we examined the distribution of care provision for patients with diabetes and CKD. Nephrology services see a minority of diabetic patients with CKD, but they see the majority of those with an estimated glomerular filtration rate (eGFR) of <30 ml/min. Of those followed in nephrology, 70% showed no evidence of progressive renal dysfunction. The nephrology cohort were significantly younger that those seen by primary care physicians or diabetologists. Half of the patients with diabetes and CKD seen in either the primary care and diabetology cohorts, with no nephrology input, had a rate of fall of eGFR of >5 ml/min/yr. This suggests that older age might deter referral to nephrology, which is based predominantly on CKD stage. This results in a significant proportion of patients with stable renal function being seen by nephrology, and in the under-referral of a large cohort of patients with progressive CKD.

Citing Articles

Dose adjustment of antidiabetic medications in chronic kidney disease.

Snyder M, Fogel J, Pyatigorskaya S, Rubinstein S Avicenna J Med. 2021; 11(1):33-39.

PMID: 33520787 PMC: 7839266. DOI: 10.4103/ajm.ajm_110_20.


A programme to spread eGFR graph surveillance for the early identification, support and treatment of people with progressive chronic kidney disease (ASSIST-CKD): protocol for the stepped wedge implementation and evaluation of an intervention to....

Gallagher H, Methven S, Casula A, Thomas N, Tomson C, Caskey F BMC Nephrol. 2017; 18(1):131.

PMID: 28399810 PMC: 5387350. DOI: 10.1186/s12882-017-0522-9.


Inhibition of 12/15-Lipoxygenase Reduces Renal Inflammation and Injury in Streptozotocin-Induced Diabetic Mice.

Faulkner J, Pye C, Al-Shabrawey M, Elmarakby A J Diabetes Metab. 2016; 6(6).

PMID: 26823989 PMC: 4727755. DOI: 10.4172/2155-6156.1000555.


Severe hyperkalaemia: demographics and outcome.

Phillips B, Milner S, Zouwail S, Roberts G, Cowan M, Riley S Clin Kidney J. 2015; 7(2):127-33.

PMID: 25852860 PMC: 4377767. DOI: 10.1093/ckj/sft158.

References
1.
Ritz E, Zeng X, Rychlik I . Clinical manifestation and natural history of diabetic nephropathy. Contrib Nephrol. 2011; 170:19-27. DOI: 10.1159/000324939. View

2.
Roland M . Linking physicians' pay to the quality of care--a major experiment in the United kingdom. N Engl J Med. 2004; 351(14):1448-54. DOI: 10.1056/NEJMhpr041294. View

3.
Meran S, Don K, Shah N, Donovan K, Riley S, Phillips A . Impact of chronic kidney disease management in primary care. QJM. 2010; 104(1):27-34. DOI: 10.1093/qjmed/hcq151. View

4.
Skupien J, Warram J, Smiles A, Niewczas M, Gohda T, Pezzolesi M . The early decline in renal function in patients with type 1 diabetes and proteinuria predicts the risk of end-stage renal disease. Kidney Int. 2012; 82(5):589-97. PMC: 3425658. DOI: 10.1038/ki.2012.189. View

5.
Nichols G, Vupputuri S, Lau H . Medical care costs associated with progression of diabetic nephropathy. Diabetes Care. 2011; 34(11):2374-8. PMC: 3198294. DOI: 10.2337/dc11-0475. View